SLN.L Share News (SLN)

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

New Serco CEO Soames marks arrival with large share purchase

Rupert Soames, who last week took up the role of Chief Executive Officer at embattled Serco Group, has given a show of faith in his own leadership - and taken advantage of the latest dip in its share price - with the purchase of 242,000 shares at 354.30p a share. The £857,406 deal gives a show of f

Silence Therapeutics Raises GBP11.4 Million In Share Placing

LONDON (Alliance News) - Silence Therapeutics PLC Tuesday said it raised gross proceeds of GBP11.4 million in a share placing.

The group had said on Monday that it was looking to raise funds in a placing with new and existing institutional investors, and certain participating direct

Silence Therapeutics Announces Plans To Raise GBP10 Million

LONDON (Alliance News) - Silence Therapeutics PLC Monday announced a share issuance to raise a minimum of GBP10 million. The group said it will raise the share placing with new and existing institutional investors, and certain participating directors will be conducted by way of an accelerat

Silence Therapeutics Expands RNA Delivery System To Multiple Tissues

LONDON (Alliance News) - Silence Therapeutics PLC said Monday that it had successfully translated data from trials with rodents of its Ribonucleic acid lung delivery system DACC to non-human primates, showing it can deliver Ribonucleic acid to multiple tissues. Ribonucleic acid is a family

Silence Therapeutics Narrows Losses; Considers Equity Fundraising

LONDON (Alliance News) - Shares in Silence Therapeutics PLC dropped Wednesday after the biotechnology company said it narrowed its losses in 2013, but is considering a potential equity fundraising for further working capital. The group said it currently holds net cash of GBP18.9 million, al

Silence Therapeutics results in-line and eyes large fundraising

Biotech company Silence Therapeutics increased research and development spending in 2013 and is now quite confident of completing a 'substantive' fundraising. The AIM-listed gene therapy specialist has received "encouraging indicative levels of interest and support" in discussions with several ins

UK MORNING BRIEFING: Antofagasta, Smiths Group Weigh On FTSE 100

LONDON (Alliance News) -Shares have opened mostly flat Wednesday ahead of UK jobs figures and budget statement.

Shares of FTSE 100 engineering firm Smiths Group were down 4.0% at the open, as it reported lower pretax profit due to the company's Medical and Defence b

Silence Therapeutics Says Progress Made On Programmes in 2013

LONDON (Alliance News) - Silence Therapeutics PLC said Thursday that it had made progress in both its pre clinic and clinical programmes during 2013, in a year end trading update. Silence said that patient enrollment for its Phase IIa trial in pancreatic cancer is progressing, and it expect

Monday broker round-up UPDATE

Aberdeen Asset Management: Goldman Sachs lowers target price from 600p to 540p, while its buy recommendation is kept. Anglo American: Deutsche Bank cuts target price from 1500p to 1460p, while leaving its hold recommendation unchanged. Credit Suisse raises target price from 1650p to 1900p upgrading

Silence Therapeutics To Test Cancer Treatment Drug Further; Chairman Steps Down

Antisoma Profits, Revenues Rise After Transition To Investing Firm

Silence Therapeutics Loss Narrows

Silence Therapeutics places 9.5m shares and plans share consolidation

Silence Therapeutics, a biotechnology company, has placed 9.5m new ordinary shares at 200p each and announced plans for a share consolidation. The placing raised net funds of £18.7m, which will be used to support the development of the RNAi platform, to broaden its skills from its pre-clinical res